Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population

International Journal of Colorectal Disease

Volumn 26, Issue 11, 2011, Pages 1387-1395

  Liou, Jyh Ming ^a,b   Wu, Ming Shiang ^a   Shun, Chia Tung ^a   Chiu, Han Mo ^a   Chen, Mei Jyh ^a   Chen, Chien Chuan ^a   Wang, Hsiu Po ^a   Lin, Jaw Town ^a,c   Liang, Jin Tung ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

Author keywords

BRAF; Chinese; Colorectal cancer; KRAS; Survival

Indexed keywords

ADULT; AGED; ARTICLE; BRAF GENE; CANCER SURVIVAL; CHINESE; CIGARETTE SMOKING; CODON; COLORECTAL CANCER; CONTROLLED STUDY; EXON; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SEX RATIO; TUMOR LOCALIZATION;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; COLORECTAL NEOPLASMS; DEMOGRAPHY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 80755132294     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-011-1229-1     Document Type: Article

References (42)

1. JJ Sung JY Lau GP Young, et al. 2008 Asia Pacific consensus recommendations for colorectal cancer screening Gut 57 1166 1176 18628378 10.1136/gut.2007.146316 1:STN:280:DC%2BD1cvlt1yitQ%3D%3D
2. JR Jass 2007 Classification of colorectal cancer based on correlation of clinical, morphological and molecular features Histopathology 50 113 130 17204026 10.1111/j.1365-2559.2006.02549.x 1:STN:280:DC%2BD2s%2FgvVOntw%3D%3D (Pubitemid 44953403)
3. A Walther E Johnstone C Swanton R Midgley I Tomlinson D Kerr 2009 Genetic prognostic and predictive markers in colorectal cancer Nat Rev Cancer 9 489 499 19536109 10.1038/nrc2645 1:CAS:528:DC%2BD1MXnsVagtbY%3D
4. JA McCubrey LS Steelman SL Abrams, et al. 2006 Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance Adv Enzyme Regul 46 249 279 16854453 10.1016/j.advenzreg.2006.01.004 1:CAS:528:DC%2BD1cXhs12lurs%3D (Pubitemid 44301348)
5. H Rajagopalan A Bardelli C Lengauer KW Kinzler B Vogelstein VE Velculescu 2002 Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status Nature 418 934 12198537 10.1038/418934a 1:CAS:528:DC%2BD38XmsFWksLs%3D (Pubitemid 34976022)
6. ST Yuen H Davies TL Chan, et al. 2002 Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia Cancer Res 62 6451 6455 12438234 1:CAS:528:DC%2BD38XovFOlu70%3D (Pubitemid 35364105)
7. H Noda Y Kato H Yoshikawa, et al. 2006 Frequent involvement of ras-signalling pathways in both polypoid-type and flat-type early-stage colorectal cancers J Exp Clin Cancer Res 25 235 242 16918136 1:CAS:528:DC%2BD28Xot1alsr4%3D (Pubitemid 44113869)
8. DW Rosenberg S Yang DC Pleau, et al. 2007 Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans Cancer Res 67 3551 3554 17440063 10.1158/0008-5472.CAN-07- 0343 1:CAS:528:DC%2BD2sXkt1KjurY%3D (Pubitemid 46762136)
9. F Di Nicolantonio M Martini F Molinari, et al. 2008 Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 5705 5712 19001320 10.1200/JCO.2008.18.0786
10. AD Siddiqui B Piperdi 2010 KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy Ann Surg Oncol 17 1168 1176 19936839 10.1245/s10434-009-0811-z
11. S Siena A Sartore-Bianchi F Di Nicolantonio J Balfour A Bardelli 2009 Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer J Natl Cancer Inst 101 1308 1324 19738166 10.1093/jnci/djp280 1:CAS:528:DC%2BD1MXht1Ojt73I
12. HJ Andreyev AR Norman D Cunningham JR Oates PA Clarke 1998 Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study J Natl Cancer Inst 90 675 684 9586664 10.1093/jnci/90.9.675 1:CAS:528:DyaK1cXjtlSiu7s%3D (Pubitemid 28222141)
13. HJ Andreyev AR Norman D Cunningham, et al. 2001 Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study Br J Cancer 85 692 696 11531254 10.1054/bjoc.2001.1964 1:CAS:528:DC%2BD3MXns1yktr8%3D (Pubitemid 32929467)
14. GM Nash M Gimbel J Shia, et al. 2010 KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases Ann Surg Oncol 17 572 578 19727962 10.1245/s10434-009-0605-3
15. GM Nash M Gimbel AM Cohen, et al. 2010 KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer Ann Surg Oncol 17 416 424 19813061 10.1245/s10434-009-0713-0
16. S Ogino K Nosho GJ Kirkner, et al. 2009 CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer Gut 58 90 96 18832519 10.1136/gut.2008.155473
17. WS Samowitz C Sweeney J Herrick, et al. 2005 Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers Cancer Res 65 6063 6069 16024606 10.1158/0008-5472.CAN-05-0404 1:CAS:528: DC%2BD2MXmt1ehtLY%3D (Pubitemid 40994390)
18. L Barault C Charon-Barra V Jooste, et al. 2008 Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases Cancer Res 68 8541 8546 18922929 10.1158/0008-5472.CAN-08-1171 1:CAS:528: DC%2BD1cXht1CmsbvK
19. DR English JP Young JA Simpson, et al. 2008 Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype Cancer Epidemiol Biomark Prev 17 1774 1780 10.1158/1055-9965.EPI-08- 0091 1:CAS:528:DC%2BD1cXosFGhtr0%3D
20. K Kumar H Brim F Giardiello, et al. 2009 Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans Clin Cancer Res 15 1155 1161 19190129 10.1158/1078-0432.CCR- 08-1029 1:CAS:528:DC%2BD1MXitVOksb4%3D
21. X Lee M Gao Y Ji, et al. 2009 Analysis of differential BRAF (V600E) mutational status in high aggressive papillary thyroid microcarcinoma Ann Surg Oncol 16 240 245 19034577 10.1245/s10434-008-0233-3
22. R Elisei C Ugolini D Viola, et al. 2008 BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study J Clin Endocrinol Metab 93 3943 3949 18682506 10.1210/jc.2008-0607 1:CAS:528:DC%2BD1cXht1Gmur3O
23. Y Ito H Yoshida R Maruo, et al. 2009 BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients Endocr J 56 89 97 18840924 10.1507/endocrj.K08E-208 1:CAS:528:DC%2BD1MXlvVWgtrg%3D
24. EJ Lee C Choi CK Park, et al. 2005 Tracing origin of serrated adenomas with BRAF and KRAS mutations Virchows Arch 447 597 602 15991007 10.1007/s00428-005-1226-2 (Pubitemid 41291632)
25. A Lindblom 2001 Different mechanisms in the tumorigenesis of proximal and distal colon cancers Curr Opin Oncol 13 63 69 11148689 10.1097/00001622- 200101000-00013 1:STN:280:DC%2BD3M7hslKguw%3D%3D (Pubitemid 32060047)
26. L Barault N Veyrie V Jooste, et al. 2008 Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers Int J Cancer 122 2255 2259 18224685 10.1002/ijc.23388 1:CAS:528:DC%2BD1cXkslynsb4%3D (Pubitemid 351542328)
27. S Benvenuti M Frattini S Arena, et al. 2008 PIK3CA cancer mutations display gender and tissue specificity patterns Hum Mutat 29 284 288 18022911 10.1002/humu.20648 1:CAS:528:DC%2BD1cXislCisL8%3D (Pubitemid 351240601)
28. AD Roth S Tejpar M Delorenzi, et al. 2010 Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial J Clin Oncol 28 466 474 20008640 10.1200/JCO.2009.23.3452 1:CAS:528:DC%2BC3cXivFartb4%3D
29. MP Weijenberg PW Aardening TM de Kok AF de Goeij PA van den Brandt 2008 Cigarette smoking and KRAS oncogene mutations in sporadic colorectal cancer: results from the Netherlands Cohort Study Mutat Res 652 54 64 18296105 1:CAS:528:DC%2BD1cXjtl2it74%3D
30. WS Samowitz H Albertsen C Sweeney, et al. 2006 Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer J Natl Cancer Inst 98 1731 1738 17148775 10.1093/jnci/djj468 1:CAS:528: DC%2BD28XhtlCru7nE (Pubitemid 44942711)
31. AJ French DJ Sargent LJ Burgart, et al. 2008 Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer Clin Cancer Res 14 3408 3415 18519771 10.1158/1078-0432.CCR-07-1489 1:CAS:528:DC%2BD1cXmslygsbo%3D
32. S Kakar G Deng V Sahai, et al. 2008 Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability Arch Pathol Lab Med 132 958 964 18517279 (Pubitemid 351918702)
33. S Lee NY Cho M Choi EJ Yoo JH Kim GH Kang 2008 Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation Pathol Int 58 104 113 18199160 10.1111/j.1440-1827.2007.02197.x 1:CAS:528:DC%2BD1cXkt1SrsLk%3D
34. I Zlobec MP Bihl H Schwarb L Terracciano A Lugli 2010 Clinico-pathological and protein characterization of BRAF and K-RAS mutated colorectal cancer and implications for prognosis Int J Cancer 127 367 380 19908233 10.1002/ijc.25265 1:CAS:528:DC%2BC3cXmsVGnt7c%3D
35. SD Richman MT Seymour P Chambers, et al. 2009 KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial J Clin Oncol 27 5931 5937 19884549 10.1200/JCO.2009.22.4295 1:CAS:528:DC%2BC3cXhtVWisL4%3D
36. ML Maestro M Vidaurreta MT Sanz-Casla, et al. 2007 Role of the BRAF mutations in the microsatellite instability genetic pathway in sporadic colorectal cancer Ann Surg Oncol 14 1229 1236 17195912 10.1245/s10434-006-9111-z 1:STN:280:DC%2BD2s7ksFClsg%3D%3D
37. N Yoshitake S Fujii K Mukawa, et al. 2007 Mutational analysis of the BRAF gene in colorectal mucinous carcinoma in association with histological configuration Oncol Rep 17 9 15 17143472 1:CAS:528:DC%2BD2sXhtFagtrg%3D
38. A Preto J Figueiredo S Velho, et al. 2008 BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations J Pathol 214 320 327 18098337 10.1002/path.2295 1:CAS:528:DC%2BD1cXivVSgt7s%3D (Pubitemid 351212387)
39. WS Samowitz K Curtin D Schaffer M Robertson M Leppert ML Slattery 2009 Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study Cancer Epidemiol Biomark Prev 9 1193 1197
40. C Wang M van Rijnsoever F Grieu, et al. 2003 Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer Oncology 64 259 265 12697967 10.1159/000069311 1:CAS:528: DC%2BD3sXivFOhtrc%3D (Pubitemid 36438811)
41. JT Liang YM Cheng KJ Chang CT Chien HC Hsu 1999 Reappraisal of K-ras and p53 gene mutations in the recurrence of Dukes' B2 rectal cancer after curative resection Hepatogastroenterology 46 830 837 10370622 1:CAS:528: DyaK1MXjs1aks70%3D
42. A Italiano I Hostein I Soubeyran, et al. 2010 KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications Ann Surg Oncol 17 1429 1434 20049644 10.1245/s10434-009- 0864-z